Table 1 Novel COVID-19 Vaccines and Therapeutics*
From: Rapid response through the entrepreneurial capabilities of academic scientists
Company | Date of first US FDA EUA issuance | Name of intervention (type of intervention) | University spin- off/collaboration with a university spin-off | US government funding prior to EUA issuance |
|---|---|---|---|---|
Eli Lilly and Company, and AbCellera Biologics Inc. | 09 November 2020 | bamlanivimab (therapeutic, mAb IV infusion) | Yes | US$375M (Oct. 2020)*** US$812M (November 2020) |
09 February 2021** | bamlanivimab and etesevimab (therapeutic, mAb IV infusion) | |||
Regeneron Pharmaceuticals Inc. | 21 November 2020 | casirivimab and imdevimab (therapeutic, mAb IV infusion) | No**** | US$82.4M (February 2020) US$85.1M (June 2020) US$450.3M (July 2020) US$15.6M (November 2020) |
Pfizer Inc. and BioNTech | 11 December 2020 | BNT162b1 (vaccine, mRNA) | Yes | US$1.95B (July 2020) |
Moderna Therapeutics and NIAID | 18 December 2020 | mRNA-1273 (vaccine, mRNA) | Yes**** | US$430.3M (April 2020) US$53.0M (May 2020) US$471.6M (July 2020) |
Janssen Biotech Inc. | 27 February 2021 | JNJ-78436735 (vaccine, Ad26) | No | US$1.0B (August 2020) |
